Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report)'s share price gapped up prior to trading on Tuesday . The stock had previously closed at $12.12, but opened at $12.89. Maze Therapeutics shares last traded at $13.35, with a volume of 12,580 shares.
Analyst Ratings Changes
A number of brokerages recently issued reports on MAZE. Guggenheim reiterated a "buy" rating and issued a $19.00 price target on shares of Maze Therapeutics in a research note on Wednesday, April 2nd. Wedbush started coverage on shares of Maze Therapeutics in a research report on Tuesday. They set an "outperform" rating and a $17.00 price objective for the company. Four equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, Maze Therapeutics has an average rating of "Buy" and an average target price of $23.50.
Read Our Latest Report on Maze Therapeutics
Maze Therapeutics Trading Up 24.3%
The stock's 50-day simple moving average is $11.22.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.39).
Hedge Funds Weigh In On Maze Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. New York State Common Retirement Fund purchased a new position in shares of Maze Therapeutics during the 1st quarter worth about $25,000. Corebridge Financial Inc. bought a new position in Maze Therapeutics during the 1st quarter valued at $48,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Maze Therapeutics during the 1st quarter valued at $57,000. Rhumbline Advisers bought a new position in shares of Maze Therapeutics in the 1st quarter worth about $80,000. Finally, Deutsche Bank AG bought a new position in shares of Maze Therapeutics in the 1st quarter worth about $98,000.
About Maze Therapeutics
(
Get Free Report)
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
Featured Articles
Before you consider Maze Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.
While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
